Table 3.
Pharmacokinetic Parameters of QP001 After Single and Multiple Administrations at 30 mg
| PK Parameters | Multiple-Dose (Day 12) (N=9) | Single-Dose (Day 1) (N=10) | P value |
|---|---|---|---|
| Cmax (μg/mL) | 12.87 ± 3.69 | 9.34 ± 2.13 | 0.02 |
| AUC0-τ (μg∙h/mL) | 130.64 ± 38.94 | 63.46 ± 12.77 | < 0.01 |
| AUC0-t (μg∙h/mL) | 245.25 ± 111.31 | 101.50 ± 29.61 | < 0.01 |
| AUC0-∞ (μg∙h/mL) | 265.60 ± 136.97 | 104.42 ± 31.96 | 0.01 |
| λz (h−1) | 0.03 ± 0.01 | 0.04 ± 0.01 | 0.04 |
| t1/2 (h) | 22.34 ± 7.03 | 17.26 ± 3.57 | 0.08 |
| Vz (L) | 7.50 ± 1.08 | 7.47 ± 1.58 | 0.97 |
| CL (mL·h−1) | 247.89 ± 70.95 | 312.13 ± 92.22 | 0.11 |
| R | 1.98 ± 0.29 | ||
Note: All values are the mean ± SD.
Abbreviations: PK, pharmacokinetic; Cmax, maximum observed plasma concentration; AUC0-τ, area under the plasma concentration time curve within the dosing interval; AUC0-t, area under the plasma concentration time curve from zero to t; AUC0-∞, area under the plasma concentration time curve from zero to infinity; λz, elimination rate constant; t1/2, terminal elimination half-life; Vz, apparent volume of distribution; CL, apparent clearance; R, accumulation index.